

BIOMARIN PHARMACEUTICAL INC

Form 4

March 20, 2008

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
BAFFI ROBERT

(Last) (First) (Middle)

**C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE**

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
**BIOMARIN PHARMACEUTICAL
INC [BMRN]**

3. Date of Earliest Transaction
(Month/Day/Year)
03/18/2008

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____X____ Officer (give title below) ____ Other (specify below)
SVP, Technical Operations

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S		100	D \$ 32.61	42,156 D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S		200	D \$ 32.62	41,956 D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S		100	D \$ 32.63	41,856 D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S		100	D \$ 32.65	41,756 D
	03/18/2008 ⁽¹⁾	03/18/2008	S		1,400	D \$ 32.66	40,356 D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.67	40,256	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	200	D	\$ 32.69	40,056	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	364	D	\$ 32.7	39,692	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.71	39,592	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.72	39,492	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	700	D	\$ 32.73	38,792	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.74	38,692	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.748	38,592	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	1,500	D	\$ 32.75	37,092	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.756	36,992	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	112	D	\$ 32.76	36,880	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.77	36,780	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	200	D	\$ 32.78	36,580	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	200	D	\$ 32.82	36,380	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.84	36,280	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	300	D	\$ 32.85	35,980	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	1,100	D	\$ 32.86	34,880	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.89	34,780	D
Common Stock	03/18/2008 ⁽¹⁾	03/18/2008	S	100	D	\$ 32.92	34,680	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Report Transaction (Instr. 10)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BAFFI ROBERT
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949

SVP, Technical Operations

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact 03/20/2008

____ Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.